Literature DB >> 32514891

Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Daniel Weintraub1,2.   

Abstract

Affective disorders (depression and anxiety), psychosis, impulse control disorders, and apathy are common and sometimes disabling psychiatric conditions in Parkinson disease (PD). Psychiatric aspects of PD are associated with numerous adverse outcomes, yet in spite of this and their high frequency, there remains incomplete understanding of epidemiology, presentation, risk factors, neural substrate, and management strategies. Psychiatric features are typically co- or multimorbid, and there is great intra- and interindividual variability in presentation [1]. The neuropathophysiological changes that occur in PD, as well as the association between PD treatment and particular psychiatric disorders, suggest a neurobiological contribution to many psychiatric symptoms. There is evidence that psychiatric disorders in PD are still under-recognized and undertreated, and although psychotropic medication use is common, randomized controlled trials demonstrating efficacy and tolerability are largely lacking. Future research on neuropsychiatric complications in PD should be oriented toward determining modifiable correlates or risk factors, and most importantly, establishing efficacious and well-tolerated treatment strategies.

Entities:  

Keywords:  Anxiety; Apathy; Depression; Impulse control disorders; Psychiatry; Psychosis

Year:  2020        PMID: 32514891      PMCID: PMC7851231          DOI: 10.1007/s13311-020-00875-w

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  217 in total

1.  Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation.

Authors:  Claire Ardouin; Valerie Voon; Yulia Worbe; Nehman Abouazar; Virginie Czernecki; Hassan Hosseini; Antoine Pelissolo; Elena Moro; Eugénie Lhommée; Anthony E Lang; Yves Agid; Alim-Louis Benabid; Pierre Pollak; Luc Mallet; Paul Krack
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

2.  Nonmotor symptoms and health-related quality of life in early Parkinson's disease.

Authors:  Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2013-12-27       Impact factor: 10.338

3.  Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.

Authors:  Sun Ju Chung; Mahnaz Asgharnejad; Lars Bauer; Francisco Ramirez; Beomseok Jeon
Journal:  Expert Opin Pharmacother       Date:  2016-07-07       Impact factor: 3.889

4.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Authors:  I H Richard; M P McDermott; R Kurlan; J M Lyness; P G Como; N Pearson; S A Factor; J Juncos; C Serrano Ramos; M Brodsky; C Manning; L Marsh; L Shulman; H H Fernandez; K J Black; M Panisset; C W Christine; W Jiang; C Singer; S Horn; R Pfeiffer; D Rottenberg; J Slevin; L Elmer; D Press; H C Hyson; W McDonald
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

5.  Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

Authors:  Daniel Weintraub; Andrew B Newberg; Mark S Cary; Andrew D Siderowf; Paul J Moberg; Galit Kleiner-Fisman; John E Duda; Matthew B Stern; David Mozley; Ira R Katz
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

6.  Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel-based morphometry.

Authors:  Jennifer S A M Reijnders; Bart Scholtissen; Wim E J Weber; Pauline Aalten; Frans R J Verhey; Albert F G Leentjens
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

Review 7.  Non motor subtypes and Parkinson's disease.

Authors:  Anna Sauerbier; Peter Jenner; Antoniya Todorova; K Ray Chaudhuri
Journal:  Parkinsonism Relat Disord       Date:  2015-09-11       Impact factor: 4.891

8.  Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.

Authors:  Kara M Smith; Sharon X Xie; Daniel Weintraub
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-11-03       Impact factor: 10.154

9.  Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.

Authors:  Robert A Hauser; Jaroslaw Slawek; Paolo Barone; Elisabeth Dohin; Erwin Surmann; Mahnaz Asgharnejad; Lars Bauer
Journal:  BMC Neurol       Date:  2016-06-07       Impact factor: 2.474

10.  Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.

Authors:  A Antonini; K R Chaudhuri; B Boroojerdi; M Asgharnejad; L Bauer; F Grieger; D Weintraub
Journal:  Eur J Neurol       Date:  2016-07-18       Impact factor: 6.089

View more
  5 in total

1.  Therapeutic Advances in Movement Disorders.

Authors:  Caroline M Tanner; Jill L Ostrem
Journal:  Neurotherapeutics       Date:  2021-01-15       Impact factor: 7.620

2.  Management of Psychiatric Disorders in Patients with Parkinson's Diseases.

Authors:  Adarsh Tripathi; Pawan Kumar Gupta; Teena Bansal
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

3.  COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson's Disease in the Elderly.

Authors:  Delfina Janiri; Martina Petracca; Lorenzo Moccia; Luca Tricoli; Carla Piano; Francesco Bove; Isabella Imbimbo; Alessio Simonetti; Marco Di Nicola; Gabriele Sani; Paolo Calabresi; Anna Rita Bentivoglio
Journal:  Front Psychiatry       Date:  2020-11-27       Impact factor: 4.157

4.  Direct Medical Costs of Parkinson's Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City.

Authors:  Hui Zhang; Wenjing Zhou; Donglan Zhang
Journal:  Int J Environ Res Public Health       Date:  2022-03-09       Impact factor: 3.390

5.  Dopamine receptor agonist rotigotine-loaded microspheres ameliorates sexual function deteriorated by fluoxetine in depression rats.

Authors:  Wenqian Wang; Ce Zhang; Yiqian Fan; Shumin Yue; Yunqi Yang; Rongxia Liu; Leiming Zhang; Tian Wang; Fenghua Fu
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.